[{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2010","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2012","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2025","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GLAND PHARMA LIMITED \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Undisclosed"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GLAND PHARMA LIMITED \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Undisclosed"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2024","type":"Financing","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Nicox SA","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Nicox SA \/ Soleus Capital","highestDevelopmentStatusID":"15","companyTruncated":"Nicox SA \/ Soleus Capital"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2019","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Nicox SA","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Nicox SA","highestDevelopmentStatusID":"15","companyTruncated":"Bausch & Lomb Incorporated \/ Nicox SA"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"HPAPI","year":"2013","type":"Inapplicable","leadProduct":"Latanoprostene Bunod","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Latanoprostene Bunod
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
